<DOC>
	<DOCNO>NCT00243880</DOCNO>
	<brief_summary>The purpose dose escalation study evaluate use lovastatin treatment acute ischemic stroke .</brief_summary>
	<brief_title>Neuroprotection With Statin Therapy Acute Recovery Trial ( Neu-START )</brief_title>
	<detailed_description>The Neuroprotection Statin Therapy Acute Recovery Trial ( Neu-START ) part Specialized Program Translational Research Acute Stroke ( SPOTRIAS ) . The overall goal SPOTRIAS enhance delivery acute stroke patient care focus high-risk , disadvantage population , train acute stroke translational researcher , conduct 3 innovative acute stroke project . Neu-START enroll 33 patient acute ischemic stroke present within 24 hour onset . In trial , investigator treat patient within 24 hour symptom onset short term high-dose lovastatin escalate dosage . The escalating dosage level 1 , 3 , 6 , 8 , 10 mg/kg per day 3 day . Lovastatin class drug call statin , use lower cholesterol prevent cardiovascular disease . Patients follow 30 day clinical laboratory outcome event . The goal trial determine lovastatin increase dos 1 mg/kg 10 mg/kg daily 3 day begin 24 hour acute ischemic stroke administer safely , assess pharmacokinetics lovastatin administer high dos .</detailed_description>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>Age &gt; 18 Satisfies criterion ischemic stroke : acute focal neurological deficit likely ischemic vascular origin . Patient legally authorize representative provide write informed consent prior study entry . Patient receive first treatment dose within 024 hour stroke onset . For patient find stroke awaken , assume stroke occur last time patient know normal . Patient pretreatment brain CT scan compatible ischemic stroke exclude hemorrhagic nonvascular etiology symptom . Patients take statins time stroke may include . Brain imaging study show lesion ischemic stroke could explain patient 's symptom ( intracranial subarachnoid hemorrhage , arteriovenous malformation , aneurysm , multiple sclerosis , tumor , abscess ) . Asymptomatic meningioma allow . Patient stroke ( ischemic hemorrhagic ) residual deficit within 1 month prior treatment . Mild stroke , define NIH Stroke Scale &lt; 2 . Patient receive expected receive intravenous rtPA within 3 hour intraarterial rtPA within 6 hour stroke onset , accord institutional standard care . Receipt intravenous rtPA 3 hour intraarterial rtPA 6 hour poststroke onset . Seizure presentation within two week prior stroke . Patient comatose , regardless etiology ( &gt; 4 point first three item NIHSS ) . History intolerance allergic reaction statin ( myotoxicity , hepatic dysfunction , rash , etc . ) Use drug within past 30 day utilize cytochrome CYP3A pathway ( cyclosporine , itraconazole , ketoconazole , erythromycin , azithromycin , clarithromycin , nefazodone ) . Use drug within past 30 day increase risk myotoxicity statin ( gemfibrozil , fibrates , niacin , amiodarone , verapamil ) . Baseline major electrolyte disturbance ( sodium &lt; 125 &gt; 150 , potassium &lt; 3.0 &gt; 5.5 ) . Recent major trauma ( &lt; 3 month ) . Hypothermia ( body temperature &lt; 96 degree Fahrenheit ) . Baseline hypoxia ( define oxygen saturation &lt; 92 % room air ) . History likely proven systemic viral infection within 30 day . Known HIV infection use protease inhibitor . Endocarditis likely cause stroke . Mitochondrial disorder likely cause stroke . Pregnancy lactation . History rhabdomyolysis , myopathy , severe muscle disease . History hepatitis , decompensated liver disease ( ascites , bleed varix encephalopathy ) , liver failure . Liver function test ( ALT , AST ) &gt; 2X upper limit normal . Unstable cardiovascular ( include uncontrolled hypertension ) , pulmonary , gastrointestinal , hepatic musculoskeletal disease within one month ( 30 day ) prior treatment ( reported history ) . Patient evidence congestive heart failure history endstage cardiovascular disease ( e.g . CHF NYHA Class III IV unstable angina ) . Abnormal ECG showing : Hemodynamically significant arrhythmia frequent PVCs ( &gt; 5/minute ) ( control atrial arrhythmia exclusion ) ; evidence acute myocardial infarction ; Mobitz Type II 2nd degree AV block 3rd degree AV block ; ventricular tachycardia ventricular fibrillation . Significant renal insufficiency , indicate serum creatinine &gt; 2.0 mg/dl . Hypoglycemia ( glucose &lt; 60 mg/dl ) , significant hyperglycemia ( glucose &gt; 400 mg/dl ) diabetic ketoacidosis . Any hematologic abnormality : Hb &lt; 10 g/dl ; WBC &lt; 3.0 x 103/mm3 ; Platelet count &lt; 50,000/mm3 Received investigational drug within 30 day . Severe behavioral social problem may interfere conduct clinical study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>acute ischemic stroke</keyword>
	<keyword>lovastatin</keyword>
	<keyword>statin</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>SPOTRIAS</keyword>
</DOC>